Tags

Type your tag names separated by a space and hit enter

Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Expert Opin Investig Drugs. 2015 Feb; 24(2):183-99.EO

Abstract

INTRODUCTION

The clinical development of anti-VEGF therapies for the treatment of exudative age-related macular degeneration (wet AMD) has revolutionized ophthalmology. Indeed, it has provided clinicians and patients with treatments that lessen visual loss from in a disease that once was uniformly blinding. Although blindness is yet to be eradicated from AMD, repeated intraocular anti-VEGF injections are required to preserve a patient's vision. Therefore, further advances in this field are necessary.

AREAS COVERED

This review provides an overview of the agents that are in mid-stage phase trials for both exudative (wet AMD) and nonexudative macular degeneration (dry AMD). For wet AMD, new agents intend to enhance efficacy, develop alternative delivery such as eye drops, investigate alternate targets and construct sustained release strategies. For advanced dry AMD, the goal is to develop a strategy to slow or stop progressive loss of retinal tissue seen in geographic atrophy, the hallmark of advanced dry AMD.

EXPERT OPINION

It is important to develop better more sensitive biomarkers, validating different approvable clinical trial endpoints and stratifying patients on their genetic polymorphisms. These developments should help to progress the already rapidly developing field of macular degeneration therapy.

Authors+Show Affiliations

University of Central Florida, College of Medicine , 6850 Lake Nona Blvd. Orlando, FL 32827 , USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25243494

Citation

Tolentino, Michael John, et al. "Drugs in Phase II Clinical Trials for the Treatment of Age-related Macular Degeneration." Expert Opinion On Investigational Drugs, vol. 24, no. 2, 2015, pp. 183-99.
Tolentino MJ, Dennrick A, John E, et al. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opin Investig Drugs. 2015;24(2):183-99.
Tolentino, M. J., Dennrick, A., John, E., & Tolentino, M. S. (2015). Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opinion On Investigational Drugs, 24(2), 183-99. https://doi.org/10.1517/13543784.2015.961601
Tolentino MJ, et al. Drugs in Phase II Clinical Trials for the Treatment of Age-related Macular Degeneration. Expert Opin Investig Drugs. 2015;24(2):183-99. PubMed PMID: 25243494.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. AU - Tolentino,Michael John, AU - Dennrick,Abrahan, AU - John,Elizabeth, AU - Tolentino,Michael Steven, Y1 - 2014/09/22/ PY - 2014/9/23/entrez PY - 2014/9/23/pubmed PY - 2015/9/15/medline KW - VEGF KW - aflibrecept KW - age related macular degeneration KW - bevacizumab KW - complement KW - fovista KW - gene therapy KW - geographic atrophy KW - ranibizumab SP - 183 EP - 99 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 24 IS - 2 N2 - INTRODUCTION: The clinical development of anti-VEGF therapies for the treatment of exudative age-related macular degeneration (wet AMD) has revolutionized ophthalmology. Indeed, it has provided clinicians and patients with treatments that lessen visual loss from in a disease that once was uniformly blinding. Although blindness is yet to be eradicated from AMD, repeated intraocular anti-VEGF injections are required to preserve a patient's vision. Therefore, further advances in this field are necessary. AREAS COVERED: This review provides an overview of the agents that are in mid-stage phase trials for both exudative (wet AMD) and nonexudative macular degeneration (dry AMD). For wet AMD, new agents intend to enhance efficacy, develop alternative delivery such as eye drops, investigate alternate targets and construct sustained release strategies. For advanced dry AMD, the goal is to develop a strategy to slow or stop progressive loss of retinal tissue seen in geographic atrophy, the hallmark of advanced dry AMD. EXPERT OPINION: It is important to develop better more sensitive biomarkers, validating different approvable clinical trial endpoints and stratifying patients on their genetic polymorphisms. These developments should help to progress the already rapidly developing field of macular degeneration therapy. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/25243494/Drugs_in_Phase_II_clinical_trials_for_the_treatment_of_age_related_macular_degeneration_ L2 - https://www.tandfonline.com/doi/full/10.1517/13543784.2015.961601 DB - PRIME DP - Unbound Medicine ER -